The use of a DNMT inhibitor reduced EMT and improved chemotherapy sensitivity in ESCC cell models, suggesting that mechanisms aiming to restore mtDNA-CN content represent a paradigm shift in therapeutic strategies for cancers [67]. This evidence concerns the gene DNMT1 and cancer.